SCHEMBL4472294

SCHEMBL4472294

CCOC(=O)c1cc(NC(=O)c2ccc(F)cc2)cc(Oc2cccnc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.65
MAPT P10636 2/20 0.65
CYP11B1 P15538 1/20 0.53
CYP11B2 P19099 1/20 0.53
KDM4E B2RXH2 3/20 0.52
KMT2A Q03164 1/20 0.51
GRM5 P41594 2/20 0.50
TSHR P16473 1/20 0.49
RAB9A P51151 4/20 0.49
NPC1 O15118 3/20 0.49
TP53 P04637 1/20 0.49
RECQL P46063 1/20 0.49
MAPK1 P28482 2/20 0.48
USP2 O75604 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TNF P01375 1/20 0.48
NOD1 Q9Y239 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
GALR3 O60755 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4478243 0.81 CYP11B1 (0.60) ALDH1A1CYP11B1CYP11B2GRM5TSHR
SCHEMBL4481536 0.81 CYP11B1 (0.69) CYP11B1CYP11B2KMT2AGRM5TSHR
SCHEMBL4492925 0.81 GRM5 (0.63) ALDH1A1CYP11B1CYP11B2GRM5RAB9A
SCHEMBL4472388 0.79 RAB9A (0.66) ALDH1A1CYP11B1CYP11B2KMT2AGRM5
SCHEMBL4466412 0.79 CYP11B1 (0.56) ALDH1A1CYP11B1CYP11B2GRM5RAB9A
SCHEMBL17104295 0.78 SMN1; SMN2 (0.69) ALDH1A1MAPTCYP11B1CYP11B2KMT2A
SCHEMBL4475675 0.77 TSHR (0.59) CYP11B1CYP11B2KMT2AGRM5TSHR
SCHEMBL4482690 0.77 CYP11B1 (0.54) ALDH1A1CYP11B1CYP11B2GRM5RAB9A
SCHEMBL4482615 0.77 CYP11B1 (0.54) ALDH1A1CYP11B1CYP11B2KMT2AGRM5
SCHEMBL12412147 0.76 GRM5 (0.61) ALDH1A1GRM5TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1503986-B1 COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE CYTOKINETICS INC (US) 2015-09-30 EP claimed
US-7605164-B2 Compositions and methods for treating heart failure CYTOKINETICS, INC. (US) 2009-10-20 US claimed
US-20060173024-A1 Compositions and methods for treating heart failure CYTOKINETICS, INC. (US) 2006-08-03 US claimed
US-7053094-B2 Compositions and methods for treating heart failure CYTOKINETICS, INC. (US) 2006-05-30 US claimed
EP-1503986-A4 COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE CYTOKINETICS INC (US) 2005-11-30 EP claimed
US-20050148638-A1 Compositions and methods for treating heart failure CYTOKINETICS, INC. (US) 2005-07-07 US claimed
US-6908923-B2 N-(3-oxy-5-functionalphenyl)(hetero)arylcarboxamide derivatives, e.g., 4-fluoro-N-(3-(pyridin-3-yloxy)-phenyl)-benzamide CYTOKINETICS, INC. (US) 2005-06-21 US claimed
EP-1503986-A2 COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE Cytokinetics, Inc. (US) 2005-02-09 EP claimed
US-20030158233-A1 Compositions and methods for treating heart failure CYTOKINETICS, INCORPORATED 2003-08-21 US claimed
WO-2003059258-A2 COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE CYTOKINETICS, INC. (US) 2003-07-24 WO claimed
EP-1503986-B1 COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE CYTOKINETICS INC (US) 2015-09-30 EP disclosed
US-7605164-B2 Compositions and methods for treating heart failure CYTOKINETICS, INC. (US) 2009-10-20 US disclosed
US-20060173024-A1 Compositions and methods for treating heart failure CYTOKINETICS, INC. (US) 2006-08-03 US disclosed
US-7053094-B2 Compositions and methods for treating heart failure CYTOKINETICS, INC. (US) 2006-05-30 US disclosed
EP-1503986-A4 COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE CYTOKINETICS INC (US) 2005-11-30 EP disclosed
US-20050148638-A1 Compositions and methods for treating heart failure CYTOKINETICS, INC. (US) 2005-07-07 US disclosed
US-6908923-B2 N-(3-oxy-5-functionalphenyl)(hetero)arylcarboxamide derivatives, e.g., 4-fluoro-N-(3-(pyridin-3-yloxy)-phenyl)-benzamide CYTOKINETICS, INC. (US) 2005-06-21 US disclosed
EP-1503986-A2 COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE Cytokinetics, Inc. (US) 2005-02-09 EP disclosed
US-20030158233-A1 Compositions and methods for treating heart failure CYTOKINETICS, INCORPORATED 2003-08-21 US disclosed
WO-2003059258-A2 COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE CYTOKINETICS, INC. (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158233-A1 Compositions and methods for treating heart failure MYH2, TNNI3, MYLK2 ALDH1A1 3435/4885MAPT 2289/4885CYP11B1 3034/4885
US-20060173024-A1 Compositions and methods for treating heart failure MYH2, TNNI3, MYLK2 ALDH1A1 3435/4885MAPT 2289/4885CYP11B1 3034/4885
US-20050148638-A1 Compositions and methods for treating heart failure MYH2, TNNI3, MYLK2 ALDH1A1 3435/4885MAPT 2289/4885CYP11B1 3034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.